Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

CELGENE CORPORATION (CELG)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Celgene pens pact to join Bristol-Myers, Pfizer in R&D race

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 12:18pm CEST

Celgene has secured an option on two preclinical assets in development at Nimbus Therapeutics. The deal gives Celgene a chance to move into the slipstreams of Bristol-Myers Squibb and Pfizer in the race to bring a TYK2 inhibitor to market.

TYK2 has attracted the interest of multiple major research groups on the strength of its role in the inflammatory response. Bristol-Myers has advanced its shot at the target, BMS-986165, into phase 2 trials in lupus and psoriasis. Pfizer is testing its TYK2-JAK1 kinase inhibitor, PF-06700841, in three phase 2 trials, which are enrolling patients with alopecia areata, ulcerative colitis and psoriasis.

Nimbus program has ceded a sizable head start to these drugs, but Celgene has seen enough in the preclinical data to suggest it can come from behind. That confidence is based, in part, on evidence Nimbus inhibitors are particularly selective for TYK2, enabling them to hit the target but not its JAK siblings.

The importance of TYK2 means there are plenty of opportunities to go around, too. A TYK2 inhibitor could treat autoimmune conditions including rheumatoid arthritis, Crohns disease and multiple sclerosis, as well as the indications being pursued in the clinic by Bristol-Myers and Pfizer.

We are excited about the potential of the Nimbus immunology targets, which are based on compelling human genetic data, Celgene R&D VP Robert Plenge, M.D., Ph.D., said in a statement. Moreover, Nimbus robust in silico-based approach is very promising.

That prompted the prolific dealmaker to put together an agreement that gives it an option to buy the program for an as-yet-undisclosed upfront payment and downstream milestones. The release of clinical trial data will trigger the buy-in decision on the TYK2 program and other assets covered by the deal. Nimbus is in charge of advancing the assets until Celgene exercises its option.

The second asset covered by the agreement is designed to block STING from activating the innate immune system in interferonopathies such as lupus. Nimbus agreement leaves it free to develop a small molecule agonist program with applications in immuno-oncology.

That immuno-oncology program is the only publicly disclosed part of Nimbus pipeline that is not yet the subject of a deal. Gilead and Genentech have already picked off other parts of the pipeline through an acquisition and licensing deal, respectively.

(c) 2017 AIN. All Rights Reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

Stocks mentioned in the article
ChangeLast1st jan.
BRISTOL-MYERS SQUIBB COMPANY -1.16% 56.06 Delayed Quote.-7.46%
CELGENE CORPORATION 0.05% 85.13 Delayed Quote.-18.46%
PFIZER -0.32% 37.22 Delayed Quote.3.06%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CELGENE CORPORATION
02:02pTODAY'S RESEARCH REPORTS ON TRENDING : Celgene and BeiGene
AC
09:56aAGIOS PHARMACEUTICALS : FDA approves Agios' IDH1 inhibitor for AML
AQ
07/20CELGENE : Inhibiting EIF2AK1 could help treat sickle cell disease
AQ
07/12CELGENE : and Acceleron Announce Luspatercept Achieved Primary and Key Secondary..
AQ
07/12CELGENE CORPORATION : - Anti-PD-L1 Immunotherapy Plus ABRAXANE Significantly Red..
AQ
07/11CELGENE : and Acceleron Announce Luspatercept Achieved Primary and All Key Secon..
AQ
07/11TODAY'S RESEARCH REPORTS ON TRENDING : Galapagos and Celgene
AC
07/11CELGENE : and Acceleron Announce Luspatercept Achieved Primary and All Key Secon..
AQ
07/11ACCELERON PHARMA : Latest luspatercept readout a second win for Acceleron, Celge..
AQ
07/10CELGENE : Health Care Shares Move Higher as Focus Shifts to Earnings -- Health C..
DJ
More news
News from SeekingAlpha
01:11pPROTAGONIST THERAPEUTICS : A Golden Opportunity Trading At A Silver Price 
10:26aBiotech Stocks Are Tariff-Safe And Building Momentum 
02:41aTop 10 Net Payout Yields - July 2018 
07/22COMPANY PROFILE : Surface Oncology 
07/19Big Pharma in the red on ramped up pressure on drug prices 
Financials ($)
Sales 2018 14 930 M
EBIT 2018 8 452 M
Net income 2018 4 841 M
Debt 2018 11 631 M
Yield 2018 -
P/E ratio 2018 13,33
P/E ratio 2019 10,50
EV / Sales 2018 4,91x
EV / Sales 2019 4,01x
Capitalization 61 683 M
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | 4-Traders
Full-screen chart
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 113 $
Spread / Average Target 32%
EPS Revisions
Managers
NameTitle
Mark J. Alles Chairman, President, CEO & COO
Peter N. Kellogg Executive VP, Chief Financial & Accounting Officer
Joseph S. Camardo Senior Vice President-Global Medical Affairs
Jay T. Backstrom Chief Medical Officer
Rupert J. Vessey President-Research & Early Development
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION-18.46%61 857
JOHNSON & JOHNSON-9.93%337 790
PFIZER3.06%218 540
NOVARTIS-0.24%206 705
ROCHE HOLDING LTD.-5.07%200 737
MERCK AND COMPANY11.11%168 171